Youssef M. K. Farag

Youssef M. K. Farag

Auto-generated profile, based on publicly available information

Youssef M. K. Farag

Renal Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2013 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
ASAjay K Singh
Ajay K Singh
YFYoussef Mk Farag
Youssef Mk Farag
BMBharati V Mittal
Bharati V Mittal
KSKuyilan Karai Subramanian
Kuyilan Karai Subramanian
SRSai Ram Keithi Reddy
Sai Ram Keithi Reddy
MRMohan M Rajapurkar
Mohan M Rajapurkar
There is a rising incidence of chronic kidney disease that is likely to pose major problems for both healthcare and the economy in future years. In India, it has been recently estimated that the age-adjusted incidence rate of ESRD to be 229 per million population (pmp), and >100,000 new patients enter renal replacement programs annually. We cross-sectionally screened 6120 Indian subjects from 13 academic and private medical centers all over India. We obtained personal and medical history data through a specifically designed questionnaire. Blood and urine samples were collected. The total cohort included in this analysis is 5588 subjects. The mean ± SD age of all participants was 45.22 ± 15.2 years (range 18–98 years) and 55.1% of them were males and 44.9% were females. The overall prevalence of CKD in the SEEK-India cohort was 17.2% with a mean eGFR of 84.27 ± 76.46 versus 116.94 ± 44.65 mL/min/1.73 m2 in non-CKD group while 79.5% in the CKD group had proteinuria. Prevalence of CKD stages 1, 2, 3, 4 and 5 was 7%, 4.3%, 4.3%, 0.8% and 0.8%, respectively. The prevalence of CKD was observed to be 17.2% with ~6% have CKD stage 3 or worse. CKD risk factors were similar to those reported in earlier studies. It should be stressed to all primary care physicians taking care of hypertensive and diabetic patients to screen for early kidney damage. Early intervention may retard the progression of kidney disease. Planning for the preventive health policies and allocation of more resources for the treatment of CKD/ESRD patients are imperative in India.

2 November 2010 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
YFYoussef M.K. Farag
Youssef M.K. Farag
MGMahmoud R. Gaballa
Mahmoud R. Gaballa
‘Diabesity’ is the term for diabetes occurring in the context of obesity. In this review, we will overview the latest epidemiological data available describing the rising prevalence, health impact and economic impact of diabesity. We will also outline the measures required to slowdown this newly evolving epidemic. The global prevalence of diabetes in 2010 was 284 million people worldwide constituting around 6.4% of the world population, which is higher than was projected in earlier studies. Furthermore, the projections for 2030 show the prevalence to reach 439 million individuals comprising ~7.7% of the world population. The burden of diabetes on the world economy has been rising steadily in the last decade to reach $376 billion in 2010 and is expected to reach $490 billion in 2030. Diabesity represents a substantial economic burden as reflected by diabetes and obesity consuming 14 and 5.7% of the USA’s total health expenditure, respectively, representing the highest known expenditure on diabesity worldwide. When costs associated with being overweight were also included, the upper limit of obesity expenditure rises to 9.1% of the USA’s total healthcare expenditure. The highest recorded expenditure on diabetes alone was in Saudi Arabia consuming 21% of the country’s total health expenditure, with no data available about the health expenditure on obesity. The health impact of diabesity is substantial to include long-term diabetic complications, reduction in health-related functioning, reduction of quality of life and reduced overall life expectancy. Long-term complications include myocardial infarction, cerebrovascular stroke and end-stage renal disease. Also recent advances have found that there is an association between chronic stress, depression and sleeping troubles to both diabetes and obesity. This century is the unprecedented diabetogenic era in human history. It is thus urgent to take steps including screening, prevention and early management in an attempt to control this evolving epidemic of diabesity.

1 May 2009 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
MAMariam P. Alexander
Mariam P. Alexander
TPTejas V. Patel
Tejas V. Patel
YFYoussef M.K. Farag
Youssef M.K. Farag
AFAdriana Florez
Adriana Florez
HRHelmut G. Rennke
Helmut G. Rennke
ASAjay K. Singh
Ajay K. Singh

28 November 2012 in Nephron Clinical Practice
Verified
Journal Article
Open access
PDF file
YFYoussef M.K. Farag
Youssef M.K. Farag
JKJameela A. Kari
Jameela A. Kari
ASAjay K. Singh
Ajay K. Singh
Chronic kidney disease (CKD) is an emerging non-communicable disease worldwide. The Arab countries have a high prevalence of CKD risk factors, e.g. diabetes, obesity and hypertension. Unfortunately, the magnitude of CKD in the Arab world has not been studied well. This review presents the current data on CKD in the Arab world and proposes a call for action to address this rising epidemic.

1 June 2011 in Clinical Nephrology
Verified
Journal Article
Closed access
YFY.M.K. Farag
Y.M.K. Farag
SKS.R. Keithi-Reddy
S.R. Keithi-Reddy
BMB.V. Mittal
B.V. Mittal
SSS.P. Surana
S.P. Surana
FAF. Addabbo
F. Addabbo
ASA.K. Singh
A.K. Singh
There is controversy regarding whether an incremental increase in hemoglobin levels is associated with improvements in health-related quality of life (HRQOL) in chronic kidney disease (CKD) patients treated with erythropoiesis-stimulating agents (ESAs). We hypothesized that HRQOL in anemic CKD patients has a multifactorial etiology, including the effects of anemia and inflammation. 69 non-dialysis CKD patients over 18 years of age with a mean estimated glomerular filtration rate (eGFR) of 43.7 ± 28.8 ml/min/1.73 m2 were divided into anemic and non-anemic cohorts. Kidney disease quality of life (KDQOL) was prospectively recorded using Short Form (SF)-36 components of KDQOL-SF-™ version 1.3 questionnaire. Inflammation was assessed by using a composite of interleukin (IL)-6, IL-8 and tumor necrosis factor (TNF)-α levels in the upper two quartiles. Anemic patients had significantly worse SF-36 components of KDQOL-SF-™ version 1.3, including SF-12 mental component (p = 0.02), role emotional (p = 0.002) and physical function (p = 0.01) compared to patients without anemia. However, in multiple linear regression models, adjusted for GFR, age, gender and inflammatory markers including C-reactive protein (CRP), albumin, ferritin, IL-6, IL-8 and TNF-α, anemia predicted mental components of SF-36 (SF-12 mental component (p = 0.02) and role emotional (p = 0.04)) but not physical components (SF-12 physical component (p > 0.05) and physical function (p > 0.05), supporting the multifactorial nature of reduced HRQOL in anemic patients. Reduced HRQOL in anemic patients is likely related to both anemic and inflammatory status. Prospective studies will be needed to evaluate whether modulating the inflammatory state independent of changes in the hemoglobin concentration improves physical components of HRQOL.

1 January 2008 in Kidney International
Verified
Journal Article
Open access
PDF file
MAM.P. Alexander
M.P. Alexander
YFY.M.K. Farag
Y.M.K. Farag
BMB.V. Mittal
B.V. Mittal
HRH.G. Rennke
H.G. Rennke
ASA.K. Singh
A.K. Singh
A 62-year-old white male, with a bipolar disorder treated with lithium, a history of type II diabetes mellitus, and hypertension, was referred to the renal clinic for evaluation of nephrotic syndrome and stage IV chronic kidney disease (CKD) (Modification of Diet in Renal Disease glomerular filtration rate 26 cc/min/1.73 m2). The patient had a history of bipolar disorder treated for over 10 years with lithium until 2 years ago when a diagnosis of nephrogenic diabetes insipidus and mild CKD was made and lithium discontinued. At that time, he had a urine osmolality of 272 mOsm/kg and a serum creatinine of 1.5 mg/dl. His medications included lisinopril, atenolol, gemfibrozil, haloperidol, quetiapine, metformin, and bupropion SR. There was no history of polyuria or polydipsia. Review of systems revealed no other significant symptoms. On examination, blood pressure was 133/64 mm Hg, heart rate 70 beats per minute, regular rhythm. Lung and cardiovascular examination were unremarkable. Abdomen was soft, nontender with no organomegaly. Extremities revealed trace edema. Urine examination revealed a specific gravity of 1.012, pH 5.5, 3+ protein, negative blood and no casts. His urine albumin creatinine ratio 3 months before was 3.9 g protein per gram creatinine. His laboratory investigations revealed BUN 40 mg/dl (reference range 9–25 mg/dl), creatinine 3.0 mg/dl (0.7–1.3 mg/dl), potassium 5.6 mEq/l (3.5–5.0 mmol/l), glucose 72 mg/dl (5–118 mg/dl), HbA1C 4.8 (4.2–5.8%), serum total proteins 6.2 g/dl (6–8 g/dl), albumin 3.5 g/dl (3.7–5.4 g/dl), cholesterol 208 mg/dl (140–199 mg/dl), triglycerides 626 mg/dl (35–150 mg/dl), low-density lipoprotein 78 mg/dl (50–129 mg/dl), hemoglobin 13.2 g/dl (11.5–16.4 g/dl), and hematocrit of 37.7% (36–48%). Complements and other serologic tests were negative. Renal ultrasound revealed bilateral nephromegaly (right kidney 12.6 cm and left kidney 12.9 cm) with a diffuse increase in echogenicity and innumerable tiny cysts throughout the kidney (cortex and medulla) (Figure 1 Figure 1 ). There was no evidence of hydronephrosis. A clinical diagnosis of nephrotic syndrome was made and it was decided to proceed to a kidney biopsy.